NiKang Therapeutics presented preclinical data on NKT5097, a first-in-class, highly potent, selective, orally bioavailable CDK2/4 dual degrader, at SABCS 2025 (December 9-12, 2025) in San Antonio, TX.1
NKT5097 selectively degrades CDK2 and CDK4 while sparing CDK1/6/7/9, aiming to inhibit pathways deeply with reduced toxicities compared to CDK4/6 inhibitors and address resistance in HR+ breast cancer and CCNE1-amplified tumors.1
Phase 1 clinical trial (NCT07029399) is ongoing as a single-agent dose escalation study evaluating safety, tolerability, PK, PD, and anti-tumor activity in advanced/metastatic solid tumors, focusing on breast cancer; first cohort dosing completed.126
Poster session: Thursday, December 11, 2025, 5:00-6:
30 PM.1
CEO Zhenhai Gao highlighted NKT5097 as the first from their CDK2/4 degrader portfolio for deeper clinical benefits.1
Sources:
1. https://www.businesswire.com/news/home/20251211303516/en/NiKang-Therapeutics-Presents-Discovery-of-NKT5097-a-First-in-Class-Highly-Potent-and-Selective-Orally-Bioavailable-CDK24-Dual-Degrader-for-Cancer-Therapy-at-SABCS-2025
2. https://www.nikangtx.com/2025/09/08/nikang-therapeutics-completes-dosing-of-the-first-cohort-in-a-phase-1-study-of-nkt5097-a-first-in-class-highly-potent-and-selective-orally-bioavailable-cdk2-4-dual-degrader/